According to a new report, published by KBV research, The Global Pruritus Therapeutics Market size is expected to reach $11.2 billion by 2030, rising at a market growth of 4.3% CAGR during the forecast period.
The Allergic Contact Dermatitis segment is showcasing a CAGR of 4.1% during (2023 - 2030). As its name suggests, allergic contact dermatitis is caused when it comes to skin contact with a specific substance. The swelling and itching that result from the contact makes the patient's skin irritated and uncomfortable. Some trigger substances include nickel, silver, or metal used in jewelry manufacture. In the personal care industry, items like soaps, cosmetics, and perfumes can also result in allergic contact dermatitis. The growing trend of tattoos and body piercings will drive the segment for allergic contact dermatitis.
The Corticosteroids segment is leading the Global Pruritus Therapeutics Market by Product in 2022; thereby, achieving a market value of $2.4 billion by 2030. Anti-inflammatory medications called corticosteroids are used for relieving pain by lowering inflammation. Cortisone, dexamethasone, prednisolone, and hydrocortisone are a few corticosteroids. Corticosteroids also reduce allergic reactions, itchiness, swelling, and redness. They are used to treat a variety of pruritus types.
The Hospital Pharmacies segment is experiencing a CAGR of 4.7% during (2023 - 2030). Hospital pharmacies are conveniently located within healthcare facilities, ensuring easy access for patients receiving treatment or care in the hospital. Patients can obtain their pruritus medications without the need for additional trips to external pharmacies. Hospital pharmacies adhere to strict regulations and quality control standards to ensure the safety and efficacy of medications. Patients can have confidence that the medications they receive are of high quality and have been properly stored and handled.
The North America region dominated the Global Pruritus Therapeutics Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $4.2 billion by 2030. The Europe region is poised to grow at a CAGR of 4.1% during (2023 - 2030). Additionally, The Asia Pacific region would experience a CAGR of 5.1% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/pruritus-therapeutics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Bristol Myers Squibb Company, Novartis AG, Pfizer, Inc., Sanofi S.A., Astellas Pharma, Inc., Cara Therapeutics, Inc., GlaxoSmithKline PLC (GSK), Teva Pharmaceuticals Industries Ltd., Amgen, Inc., and AbbVie, Inc.
By Disease Type
By Product
By Distribution Channel
By Geography
Companies Profiled
Unique Offerings 
